Cantor Fitzgerald Reconfirms Alnylam Pharma (NASDAQ:ALNY) As a “Buy”; They Now Have a Price Objective Of $135.0000

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Investors sentiment increased to 1.61 in Q2 2018. Its up 0.21, from 1.4 in 2018Q1. It increased, as 33 investors sold Alnylam Pharmaceuticals, Inc. shares while 60 reduced holdings. 57 funds opened positions while 93 raised stakes. 92.05 million shares or 3.13% more from 89.26 million shares in 2018Q1 were reported.

427,740 were accumulated by American Century Inc. Eaton Vance Mngmt owns 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 37,791 shares. Wells Fargo & Comm Mn owns 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 196,803 shares. Tekla Limited Co holds 0.49% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 130,376 shares. Atika Mgmt Ltd Limited Liability Company invested in 23,000 shares. Asset Management has 0.03% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 54,368 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 18,314 shares or 0.02% of all its holdings. Vigilant Management Ltd Liability stated it has 500 shares. Earnest Prns Ltd reported 27 shares stake. United Automobile Association has 3.48M shares for 0.56% of their portfolio. Captrust Financial holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 150 shares. Moreover, Ameriprise Fincl has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 104,268 shares. Millennium Mngmt Ltd Liability Com invested in 2,182 shares or 0% of the stock. Weiss Asset L P reported 2,460 shares or 0.02% of all its holdings. Baillie Gifford reported 4.23M shares stake.

Since May 31, 2018, it had 0 insider buys, and 2 selling transactions for $5.57 million activity. MARAGANORE JOHN sold 50,000 shares worth $5.27M. The insider Greenstreet Yvonne sold $300,000.

Alnylam Pharma (NASDAQ:ALNY) Rating Reaffirmed

Cantor Fitzgerald now has a $135.0000 target price per share on shares of Alnylam Pharma (NASDAQ:ALNY). The target price per share means a potential upside of 66.34 % from the last stock close of Alnylam Pharma (NASDAQ:ALNY). This rating was revealed in a research report on Wednesday, 28 November.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 9 analysts covering Alnylam Pharma (NASDAQ:ALNY), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Alnylam Pharma has $230 highest and $63 lowest target. $126.22’s average target is 55.52% above currents $81.16 stock price. Alnylam Pharma had 15 analyst reports since June 27, 2018 according to SRatingsIntel. The company was maintained on Wednesday, June 27 by Piper Jaffray. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by Cowen & Co on Monday, August 13. FBR Capital maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Monday, August 13 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Stifel Nicolaus on Thursday, September 13. Stifel Nicolaus upgraded the shares of ALNY in report on Tuesday, August 7 to “Buy” rating. The rating was maintained by Stifel Nicolaus on Monday, August 13 with “Buy”. As per Tuesday, October 16, the company rating was maintained by BMO Capital Markets. The company was maintained on Wednesday, November 28 by Cantor Fitzgerald. The rating was maintained by Morgan Stanley with “Equal-Weight” on Friday, September 28. Nomura maintained the stock with “Reduce” rating in Monday, August 13 report.

The stock increased 0.68% or $0.55 during the last trading session, reaching $81.16. About 775,613 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 19.20% since December 2, 2017 and is uptrending. It has outperformed by 3.58% the S&P500.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company has market cap of $8.20 billion. The Company’s pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. It currently has negative earnings. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis ; Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Nasdaq.com which released: “Health Care Sector Update for 11/26/2018: RSLS,ALNY,EDGE,BHVN – Nasdaq” on November 26, 2018, also Fool.com with their article: “Alnylam Pharmaceuticals Launches Onpattro – The Motley Fool” published on November 15, 2018, Nasdaq.com published: “Noteworthy Monday Option Activity: ALNY, ACOR, EROS – Nasdaq” on September 10, 2018. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Seekingalpha.com and their article: “It’s Time To Buy Microsoft – Cramer’s Lightning Round (11/2/18) – Seeking Alpha” published on November 05, 2018 as well as Seekingalpha.com‘s news article titled: “Making Sense Of Alnylam’s Valuation – Seeking Alpha” with publication date: September 24, 2018.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.